| FDESX | RGACX | FDESX / RGACX | |
| Total Expense Ratio | 0.41 | 0.93 | 44% |
| Annual Report Gross Expense Ratio | 0.41 | 0.93 | 44% |
| Fund Existence | 56 years | 24 years | - |
| Gain YTD | 14.823 | 9.283 | 160% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 250 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 4.21B | 353B | 1% |
| Annual Yield % from dividends | 0.45 | 0.00 | - |
| Returns for 1 year | 12.94 | 0.87 | 1,487% |
| Returns for 3 years | 44.34 | 41.63 | 107% |
| Returns for 5 years | 18.07 | 11.29 | 160% |
| Returns for 10 years | 107.07 | 101.73 | 105% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RYCFX | 53.90 | N/A | N/A |
| Rydex Biotechnology C | |||
| FDTCX | 37.28 | N/A | N/A |
| Fidelity Advisor Diversified Stock C | |||
| VLACX | 142.54 | N/A | N/A |
| Vanguard MStar Large Cap Index Investor | |||
| CRIHX | 13.29 | N/A | N/A |
| CRM Long/Short Opportunities Instl | |||
| AVEEX | 18.29 | -0.06 | -0.33% |
| Avantis® Emerging Markets Equity Instl | |||